DE60313785D1 - Kombinierte verwendung von melatonin und methylphenidat zur behandlung von aufmerksamkeits-/hyperaktivitätsstörungen. - Google Patents
Kombinierte verwendung von melatonin und methylphenidat zur behandlung von aufmerksamkeits-/hyperaktivitätsstörungen.Info
- Publication number
- DE60313785D1 DE60313785D1 DE60313785T DE60313785T DE60313785D1 DE 60313785 D1 DE60313785 D1 DE 60313785D1 DE 60313785 T DE60313785 T DE 60313785T DE 60313785 T DE60313785 T DE 60313785T DE 60313785 D1 DE60313785 D1 DE 60313785D1
- Authority
- DE
- Germany
- Prior art keywords
- melatonin
- combined use
- methylphenide
- hyperactivity disorders
- treat attention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title abstract 4
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title abstract 3
- 229960003987 melatonin Drugs 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000013403 hyperactivity Diseases 0.000 title 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 abstract 2
- 229960001344 methylphenidate Drugs 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02021810 | 2002-09-26 | ||
| EP02021810 | 2002-09-26 | ||
| PCT/EP2003/010827 WO2004028532A1 (en) | 2002-09-26 | 2003-09-26 | Combined use of methylphenidate and melatonin for treating attention-deficit hyperactive disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60313785D1 true DE60313785D1 (de) | 2007-06-21 |
| DE60313785T2 DE60313785T2 (de) | 2008-01-24 |
Family
ID=32039113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60313785T Expired - Lifetime DE60313785T2 (de) | 2002-09-26 | 2003-09-26 | Kombinierte verwendung von melatonin und methylphenidat zur behandlung von aufmerksamkeits-/hyperaktivitätsstörungen. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060167050A1 (de) |
| EP (1) | EP1545511B1 (de) |
| AT (1) | ATE361747T1 (de) |
| AU (1) | AU2003270292A1 (de) |
| CA (1) | CA2500198A1 (de) |
| DE (1) | DE60313785T2 (de) |
| ES (1) | ES2287512T3 (de) |
| WO (1) | WO2004028532A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2507517T3 (es) * | 2008-01-31 | 2014-10-15 | Takeda Pharmaceutical Company Limited | Agente profiláctico o terapéutico para trastorno de déficit de atención con hiperactividad |
| UA107653U (uk) * | 2012-10-01 | 2016-06-24 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5449683A (en) * | 1992-10-01 | 1995-09-12 | Massachussetts Institute Of Technology | Methods of inducing sleep using melatonin |
| US5654325A (en) * | 1993-11-18 | 1997-08-05 | Eli Lilly And Company | Melatonin derivatives for use in treating sleep disorders |
| US6121261A (en) * | 1997-11-19 | 2000-09-19 | Merck & Co., Inc. | Method for treating attention deficit disorder |
| CA2357114C (en) * | 2001-03-22 | 2010-06-29 | Pooger Properties Ltd. | Use of melatonin in the manufacture of a medicament for treating attention deficit hyperactive disorder |
-
2003
- 2003-09-26 AU AU2003270292A patent/AU2003270292A1/en not_active Abandoned
- 2003-09-26 ES ES03750659T patent/ES2287512T3/es not_active Expired - Lifetime
- 2003-09-26 CA CA002500198A patent/CA2500198A1/en not_active Abandoned
- 2003-09-26 DE DE60313785T patent/DE60313785T2/de not_active Expired - Lifetime
- 2003-09-26 EP EP03750659A patent/EP1545511B1/de not_active Expired - Lifetime
- 2003-09-26 AT AT03750659T patent/ATE361747T1/de active
- 2003-09-26 US US10/529,341 patent/US20060167050A1/en not_active Abandoned
- 2003-09-26 WO PCT/EP2003/010827 patent/WO2004028532A1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ATE361747T1 (de) | 2007-06-15 |
| WO2004028532A1 (en) | 2004-04-08 |
| US20060167050A1 (en) | 2006-07-27 |
| EP1545511A1 (de) | 2005-06-29 |
| DE60313785T2 (de) | 2008-01-24 |
| ES2287512T3 (es) | 2007-12-16 |
| EP1545511B1 (de) | 2007-05-09 |
| AU2003270292A1 (en) | 2004-04-19 |
| CA2500198A1 (en) | 2004-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| DE60207383D1 (de) | Ibuprofen und diphenhydramin enthaltende zusammensetzungen und deren verwendung zur behandlung von schlafstörungen | |
| ATE451376T1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
| ATE482213T1 (de) | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine | |
| EA200602062A1 (ru) | Амидосоединения и их применение в качестве фармацевтических средств | |
| ATE464303T1 (de) | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen | |
| DE69805202D1 (de) | Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs | |
| ATE337780T1 (de) | Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns | |
| DE602004031134D1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
| ATE497809T1 (de) | Myricitrin verbindungen zur behandlung von schlafstörungen | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| DE60112766D1 (de) | Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen | |
| ATE473728T1 (de) | Verwendung von fluoreszierenden perlylenverbindungen zur behandlung menschlicher haare | |
| ATE275400T1 (de) | Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ | |
| NO20082679L (no) | Sammensetning og fremgangsmate for a behandle CNS lidelser | |
| DE60008753D1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| DE69825286D1 (de) | Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen | |
| MXPA05013226A (es) | Carbamatos de piperidina sustituidos, para el uso como inhibidores de la lipasa sensible a hormonas. | |
| DE602004028574D1 (de) | Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie | |
| DE60313785D1 (de) | Kombinierte verwendung von melatonin und methylphenidat zur behandlung von aufmerksamkeits-/hyperaktivitätsstörungen. | |
| DE60018704D1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| ATE406158T1 (de) | Verwendung von vitamin c zur behandlung der charcot-marie-tooth krankheit | |
| NO20071466L (no) | 3-substituerte-5- og 6-aminoalkyl indol-2-karboksylsyreamider og relaterte analoger som inhibitorer av kaseinkinase IE | |
| ATE361071T1 (de) | Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |